For research and educational purposes only. Not medical advice.
FOXO4-DRI Reference
Educational, not medical advice reference for FOXO4-DRI: Longevity, Recovery; regulatory status, evidence posture, source review, and schedule n…
Reference summary
Mouse and cell-model studies report FOXO4-p53 disruption and senescent-cell targeting. Human efficacy and safety data are absent.
Regulatory and posture
- Categories
- Longevity, Recovery
- Aliases
- FOXO4-D-Retro-Inverso, FOXO4-p53 interfering peptide, Senolytic peptide
- Evidence posture
- preclinical - Preclinical senolytic. Anti-aging and fertility claims are animal / cell-model extrapolations. Removing senescent cells may carry biology-specific risks that have not been resolved in humans.
- Regulatory status
- No FDA-approved FOXO4-DRI drug label. Published work is preclinical and mechanistic; there is no approved senolytic peptide product for anti-aging, fertility, fibrosis, or cancer-adjunct use.
- Content review status
- research reference
Selected public sources
- FDA bulk drug substances with significant safety risks
- PubMed: FOXO4-DRI targeted apoptosis of senescent cells
- PubMed: FOXO4-DRI pulmonary-fibrosis mouse study
- PubMed: FOXO4-DRI aged-mouse spermatogenesis study
Related tools
- Injection-site rotation overview - Public overview of the Pro site-rotation planner.
- Protocol builder overview - Public overview of the Pro protocol builder.